Results 31 to 40 of about 50,442 (246)

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

Frontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu, TianDuo Wang, John A. Ronald, John A. Ronald   +3 more
doaj   +1 more source

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor [PDF]

Journal of Immunotherapy, 2009
T cells can be engineered to express the genes of chimeric antigen receptors (CARs) that recognize tumor-associated antigens. We constructed and compared 2 CARs that contained a single chain variable region moiety that recognized CD19. One CAR contained the signaling moiety of the 4-1BB molecule and the other did not.
James N, Kochenderfer, Steven A, Feldman, Yangbing, Zhao, Hui, Xu, Mary A, Black, Richard A, Morgan, Wyndham H, Wilson, Steven A, Rosenberg   +7 more
openaire   +2 more sources

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Frontiers in Oncology, 2022
BackgroundThe CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor ...
Yuanyuan Liu, Yanxin Zheng, Tianyi Deng, Yue Huang, Ziwen Liu, Borui Zhan, Xusha Zhou, Runbin Yan, Jiangtao Ren, Yun Xing, Guixing Wu, Biao Zheng, Guang Hu, Wen Wang, Yonghong Liu, Jing Zhao, Xiaoqing Chen, Grace Guoying Zhou   +17 more
doaj   +1 more source

Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report

Biomarker Research, 2020
Background Mixed phenotype acute leukemia (MPAL) is a rare leukemia and is regarded as a high-risk entity with a poor prognosis. Induction therapy of an acute lymphoblastic leukemia type or hybrid regimen and hematopoietic stem cell transplantation has ...
Meng-Yun Li, Zhi-Hong Lin, Ming-Ming Hu, Li-Qing Kang, Xiao-xia Wu, Qi-wei Chen, Xin Kong, Jian Zhang, Hui-Ying Qiu, De-Pei Wu   +9 more
doaj   +1 more source

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies

Journal of Immunology Research, 2021
Natural killer (NK) cells are part of the first line of defense that rapidly respond to malignant transformed cells. Chimeric antigen receptor- (CAR-) engineered NK cells, although are still at the preliminary stage, have been shown to be alternative to ...
Sudjit Luanpitpong, Jirarat Poohadsuan, Phatchanat Klaihmon, Surapol Issaragrisil   +3 more
doaj   +1 more source

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges

Hematology/Oncology and Stem Cell Therapy, 2022
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in ...
Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S. Majhail   +4 more
doaj   +1 more source

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function

Blood Advances, 2023
Abstract Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens
Isabel Leung, Megan L. Templeton, Yun Lo, Anusha Rajan, Sylvia M. Stull, Sarah M. Garrison, Alexander I. Salter, Kimberly S. Smythe, Colin E. Correnti, Shivani Srivastava, Cecilia C. S. Yeung, Stanley R. Riddell   +11 more
openaire   +2 more sources

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Journal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung, Nattiya Hirankarn, Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Alexander McLellan, Koramit Suppipat   +6 more
doaj   +1 more source

Fully human CD19-specific chimeric antigen receptors for T-cell therapy [PDF]

Leukemia, 2017
Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune responses specific for peptides from the murine scFv antigen-binding domain of the CAR can develop in patients and result in premature elimination of CAR T ...
Sommermeyer, Daniel, Hill, Tyler, Shamah, Steven M, Salter, Alexander I, Chen, Yan, Mohler, Kendall M., Riddell, Stanley R.   +6 more
openaire   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source